20.5 C
New York
Thursday, June 18, 2026

Tag: treatments

newssourceFORcompanyinformationcontent1marketreleases

HelloNation Article Explains Protecting Eyes From Kentucky Allergies Featuring Optometry Expert Dr. Kimberly Arnett

The article clarifies how to distinguish allergy symptoms from infections and outlines steps to reduce irritation and protect eye health.FLORENCE, Ky., June 2, 2026...

Demand for Compounding Pharmacies in USA to Reach USD 12.79 Billion by 2036 Amid Growing Need for Personalized Therapies and Specialized Medication Solutions

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

ohDEER Expands to Portland, Maine, Bringing All-Natural Deer, Tick, Mosquito and Rabbit Control to Local Families

ohDEER Portland ME marks the company's twenty-first location.PORTLAND, Maine, June 2, 2026 /PRNewswire/ -- ohDEER, a leading provider of all-natural deer, tick, mosquito, and...

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

CNI (Hong Kong) Yuanqizhi International Limited Launches Father’s Day Family Wellness Package Combining In-Home Pain Management and Nutritional Solutions

CNI (Hong Kong) Yuanqizhi International Limited launches its Father's Day Family Wellness Package, blending in-home pain management and nutrition

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working...

Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /CNW/ - Hydreight...

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Spectrum Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline –...

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces the reopening of the Lead Plaintiff appointment process in a pending securities class action lawsuit on behalf of investors of Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI). Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Sonicsmooth Pro+ Brings Professional-Style Dermaplaning and Exfoliation Home in 2025

At-home dermaplaning and exfoliation tool for smoother, brighter-looking skin 
At-home dermaplaning and exfoliation tool for smoother, brighter-looking skin

BioSig Technologies, Inc. & Streamex Announce Closing of $15 Million Public Offering

Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants 
Offering Structured to Accelerate Streamex’s Operational Build-Out, Strategically Allocated with No Warrants

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTreatments

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers